Strata Critical Medical (SRTA) Cash from Investing Activities (2019 - 2026)

Strata Critical Medical has disclosed Cash from Investing Activities across 7 years of filings, most recently posting $24.7 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 21.18% year-over-year to $24.7 million; the TTM figure through Mar 2026 stood at $74.1 million (up 1532.45% YoY), while the FY2025 annual figure was $69.8 million, up 6965.16% from the prior year.
• Cash from Investing Activities rose to $24.7 million in Q1 2026, from $18.3 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for SRTA reached as high as $207.6 million in Q2 2022 and fell as low as -$16.9 million in Q2 2024.
• The 5-year median for Cash from Investing Activities is $11.0 million (2022), against an average of $21.9 million.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities soared 20849.06% — and 2024, when it tumbled 548.01%.
• A 5-year view of Cash from Investing Activities shows it stood at $207.6 million in 2022, then sank by 99.96% to $75000.0 in 2023, then soared by 5201.33% to $4.0 million in 2024, then surged by 359.38% to $18.3 million in 2025, then surged by 35.39% to $24.7 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $24.7 million, $18.3 million, and $2.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.